Rhythm Pharmaceuticals Reacquires Rights to IMCIVREE® (setmelanotide) in China, Hong Kong, and Macau

 Rhythm Pharmaceuticals, Inc., a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neur...

March 24, 2025 | Monday | News
Paratek Pharmaceuticals to Acquire Optinose for Up to $330 Million, Expanding Portfolio with XHANCE®

Paratek Pharmaceuticals and Optinose, Inc. announced they have entered into a definitive merger agreement under which Paratek will acquire Optinose, includ...

March 21, 2025 | Friday | News
Ionis and Ono Pharmaceutical Partner on Sapablursen for Polycythemia Vera with Exclusive Global Rights Agreement

 Ionis Pharmaceuticals, Inc. and Ono Pharmaceutical Co., Ltd (Ono), announced that the two companies have entered into a license agreement in whi...

March 12, 2025 | Wednesday | News
CordenPharma Commits >€1 Billion to Expand Peptide Manufacturing Across Europe and the US

  CordenPharma is making a record investment of >€1 billion over the next 3 years in building and / or expanding small, medium, and la...

March 05, 2025 | Wednesday | News
Callio Therapeutics Launches with $187M Series A for ADC Cancer Therapy

Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, a...

March 04, 2025 | Tuesday | News
Avecho Biotechnology Partners with Sandoz for Exclusive Australian Rights to CBD Insomnia Capsule

Avecho Biotechnology Limited  announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG ("Sandoz") for th...

March 04, 2025 | Tuesday | News
Rapid Micro Biosystems Partners with MilliporeSigma for Global Distribution and Collaboration on Growth Direct Systems

Rapid Micro Biosystems, Inc. (the “Company” or “Rapid Micro”), an innovative life sciences technology company providing mission cri...

February 28, 2025 | Friday | News
Nxera Pharma Signs Agreement with Viatris and Idorsia for Cenerimod Development and Commercialization in Japan, South Korea, and APAC

Nxera Pharma has entered an assignment agreement with Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Pharmaceuticals Ltd (&...

February 28, 2025 | Friday | News
Celltrion Secures FDA Approval for AVTOZMA® Biosimilar to ACTEMRA® with Both IV and SC Formulations

Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) ...

February 12, 2025 | Wednesday | News
Alumis and ACELYRIN Announce Definitive Merger Agreement, Creating a Leading Immunology Biopharma with Late-Stage Pipeline Strength

Alumis Inc. (Nasdaq: ALMS) and ACELYRIN, Inc. (Nasdaq: SLRN) today announced a definitive merger agreement, creating a powerhouse in immunology-focused b...

February 07, 2025 | Friday | News
Neurocrine Biosciences Secures Global Rights to Osavampator, a Potential Breakthrough Treatment for Major Depressive Disorder

 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced it has amended its agreement with Takeda to develop and commercialize osavampator (NB...

January 28, 2025 | Tuesday | News
Norgine and X4 Pharmaceuticals Celebrate EMA Validation of Mavorixafor for WHIM Syndrome

Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 that their Marketing Authorization Applicatio...

January 27, 2025 | Monday | News
Tevogen Bio Expands AI Partnership with Microsoft to Accelerate Immunotherapy Development

Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech d...

January 27, 2025 | Monday | News
AbbVie and Neomorph Forge Partnership to Develop Novel Molecular Glue Degraders for Oncology and Immunology

AbbVie (NYSE: ABBV) and Neomorph, Inc. announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple tar...

January 24, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close